IPO registrations (S-1, F-1) · Registrants
Immuron Ltd
- SEC CIK
- 1660046 · filings on EDGAR ↗
- Registration
- Form F-1, first filed 2016-12-21, last 2017-05-26; 1 initial registration, 8 amendments
- Outcome
- Final prospectus filed 2017-06-12; declared effective 2017-06-08; withdrawal requested 2019-04-08
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- C3
- Business address
- 62 LYGON STREET, LEVEL 3, Carlton, Victoria, C3 3053
- Ticker
- IMRN (Nasdaq)
- EDGAR entity type
- other
- Insiders and CEO pay
- Immuron Ltd on the corporate pages
Offering terms
- Proposed price range
- $10.00–$12.50 per ADS (F-1/A filed 2017-05-24)
- Final price
- $10.00 per ADS, within the range (424B4 filed 2017-06-12, an initial public offering)
- Shares sold
- 610,000
- Gross proceeds
- $6,100,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol IMRN
- Lead underwriters
- H.C. Wainwright
- Syndicate
- Joseph Gunnar; Rodman & Renshaw; WallachBeth Capital
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- SEC filer: Immuron Ltd EXACT (CIK (EXACT))
Filings 16
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2016-12-21 | F-1 | F-1 (foreign registration) | Immuron Ltd | 0001615774-16-008996 ↗ |
| 2017-02-09 | F-1/A | F-1/A (amendment) | Immuron Ltd | 0001615774-17-000429 ↗ |
| 2017-04-10 | F-1/A | F-1/A (amendment) | Immuron Ltd | 0001615774-17-001568 ↗ |
| 2017-04-28 | F-1/A | F-1/A (amendment) | Immuron Ltd | 0001615774-17-001908 ↗ |
| 2017-05-08 | F-1/A | F-1/A (amendment) | Immuron Ltd | 0001615774-17-002101 ↗ |
| 2017-05-22 | F-1/A | F-1/A (amendment) | Immuron Ltd | 0001615774-17-002554 ↗ |
| 2017-05-24 | F-1/A | F-1/A (amendment) | Immuron Ltd | 0001615774-17-002646 ↗ |
| 2017-05-25 | F-1/A | F-1/A (amendment) | Immuron Ltd | 0001615774-17-002679 ↗ |
| 2017-05-26 | F-1/A | F-1/A (amendment) | Immuron Ltd | 0001615774-17-002719 ↗ |
| 2017-06-08 | F-1MEF | F-1MEF (added securities) | Immuron Ltd | 0001615774-17-003067 ↗ |
| 2017-06-08 | EFFECT | EFFECT (declared effective) | Immuron Ltd | 9999999995-17-001480 ↗ |
| 2017-06-12 | 424B4 | 424B4 (final prospectus) | Immuron Ltd | 0001615774-17-003091 ↗ |
| 2017-06-13 | 424B4 | 424B4 (final prospectus) | Immuron Ltd | 0001615774-17-003120 ↗ |
| 2019-02-11 | EFFECT | EFFECT (declared effective) | Immuron Ltd | 9999999995-19-000148 ↗ |
| 2019-04-08 | RW | RW (withdrawal request) | Immuron Ltd | 0001615774-19-005428 ↗ |
| 2019-04-17 | EFFECT | EFFECT (declared effective) | Immuron Ltd | 9999999995-19-000748 ↗ |
Prospectus pages read 4
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2017-05-24 | F-1/A | registration statement | $10.00–$12.50 | 777,778 | - | Nasdaq IMRN | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2017-05-25 | F-1/A | registration statement | - | - | 0 | primary document; no terms found | document ↗ | |||
| 2017-05-26 | F-1/A | registration statement | - | - | 0 | primary document; no terms found | document ↗ | |||
| 2017-06-12 | 424B4 | final prospectus | $10.00 | 610,000 | $6,100,000 | Nasdaq IMRN | 4 | primary document; price table, shares headline, proceeds computed, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Joughin Jeannette Anne | Director | 1 | 2026 | ||
| Kanellos Jerry | Officer | Chief Scientific Officer | 1 | 2026 | |
| Laurita Aaron James | Officer | Chief Financial Officer | 1 | 2026 | |
| Lydeamore Steven George | Officer | Chief Executive Officer | 1 | 2026 | |
| Savarirayan Ravi | Director | 1 | 2026 | ||
| Brennan Paul Gerard | Director,Officer | Chairman of the Board | 1 | 2026 | |
| Palumbo Flavio | Officer | Chief Commercial Officer | 1 | 2026 | |
| Pollock Daniel Jude | Director | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| SEC filer | Immuron Ltd | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, C3 first:
- Pharmaxis Ltd. C3
- Propanc Biopharma, Inc. C3
- Benitec Biopharma LTD/ADR C3
- Parnell Pharmaceuticals Holdings Ltd C3
- Beroni Group Ltd C3
- Medlab Clinical Ltd. C3
- Telix Pharmaceuticals Ltd C3
- MorphoSys AG 2M
- Affimed N.V. 2M
- InflaRx N.V. 2M
In other datasets, the same topic (Health) in C3:
- Form D issuer: Botanix Pharmaceuticals Ltd. (Form D private offerings)
Interests: Pharmaceutical Preparations · Health